Skip to main content
SpringerLink
Log in

Juvenile Dermatomyositis in Adolescents and Young Adults

  • Chapter
  • First Online:
Adolescent and Young Adult Rheumatology In Clinical Practice

Part of the book series: In Clinical Practice ((ICP))

  • 575 Accesses

Abstract

Juvenile dermatomyositis (JDM) is a rare disease but the most common idiopathic inflammatory myopathy (IIM) of childhood. It is a systemic vasculopathy primarily affecting the skin and muscles, causing classic signs of rash and proximal muscle weakness, but can present with heterogeneous features, natural history and outcomes. This chapter highlights the differences between paediatric and adult disease in clinical presentation and presents an update of treatment strategies and outcomes of the disease including cardiovascular involvement, reproductive health and vocational developmental milestones.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 34.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 44.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cattalini M, Soliani M, Caparello MC, Cimaz R. Sex differences in pediatric rheumatology. Clin Rev Allergy Immunol. 2017. https://doi.org/10.1007/s12016-017-8642-3.

  2. Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, Abbott K, Mendez EP, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 2005;53(2):166–72.

    Article  Google Scholar 

  3. Boros C, McCann L, Ambrose N, Cortina-Borja M, Simou S, Pilkington C. Juvenile dermatomyositis: what comes next? Arthritis Rheumatol. 2016;68(Suppl 10).

    Google Scholar 

  4. Martin N, Krol P, Smith S, Beard L, Pilkington CA, Davidson J, et al. Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study. Arthritis Care Res (Hoboken). 2012;64(11):1665–72.

    Article  CAS  Google Scholar 

  5. Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther. 2013;15(2):211. Epub 2013/04/10

    Article  PubMed Central  Google Scholar 

  6. Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2014;16(12):467.

    Article  PubMed Central  Google Scholar 

  7. Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223–43.

    Article  CAS  Google Scholar 

  8. Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 2014;16(4):R138.

    Article  PubMed Central  Google Scholar 

  9. Varsani H, Charman SC, Li CK, Marie SK, Amato AA, Banwell B, et al. Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease. Ann Rheum Dis. 2015;74(1):204–10.

    Article  PubMed Central  Google Scholar 

  10. Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, et al. Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. Arthritis Rheumatol. 2016;68(11):2806–16.

    Article  CAS  PubMed Central  Google Scholar 

  11. Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken). 2012;64(4):546–53.

    Article  Google Scholar 

  12. Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SD, et al. Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. J Rheumatol. 2017;44(1):110–6.

    Article  CAS  PubMed Central  Google Scholar 

  13. Kim S, Kahn P, Robinson AB, Lang B, Shulman A, Oberle EJ, et al. Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J. 2017;15(1):1.

    Article  PubMed Central  Google Scholar 

  14. Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF, Subgroup CJM. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). Pediatr Rheumatol Online J. 2017;15(1):71.

    Article  CAS  PubMed Central  Google Scholar 

  15. Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329–40.

    Article  PubMed Central  Google Scholar 

  16. Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, et al. Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling. Arthritis Rheumatol. 2018;70:785–93.

    Article  CAS  PubMed Central  Google Scholar 

  17. Campanilho-Marques R, Deakin CT, Simou S, Wedderburn LR, Pilkington C. Efficacy and safety of tumour necrosis factor antagonists in a large cohort of juvenile dermatomyositis patients [abstract]. Ann Rheum Dis. 2016;75(Suppl 2):140.

    Article  Google Scholar 

  18. Cabrera N, Duquesne A, Desjonqueres M, Larbre JP, Lega JC, Fabien N, et al. Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children. RMD Open. 2016;2(2):e000271.

    Article  PubMed Central  Google Scholar 

  19. Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine. 2011;78(4):431–2.

    Article  PubMed Central  Google Scholar 

  20. Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009;60(11):3436–46.

    Article  CAS  PubMed Central  Google Scholar 

  21. McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, et al. Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Ann Rheum Dis. 2018;77(2):241–50.

    Article  PubMed Central  Google Scholar 

  22. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63–72.

    Article  Google Scholar 

  23. Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2014;66(5):732–40.

    Article  Google Scholar 

  24. Schwartz T, Diederichsen LP, Lundberg IE, Sjaastad I, Sanner H. Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies. RMD Open. 2016;2(2):e000291.

    Article  PubMed Central  Google Scholar 

  25. Papadopoulou C, Hong Y, Krol P, Y I, C P, H C, et al. The vasculopathy of Juvenile Dermatomyositis (JDM): evidence of persistent endothelial injury, hypercoagulability, subclinical inflammation and increased arterial stiffness. Arthritis Rheumatol. 2016;68(Suppl 10).

    Google Scholar 

  26. Chen JS, Roberts CL, Simpson JM, March LM. Pregnancy outcomes in women with rare autoimmune diseases. Arthritis Rheumatol. 2015;67(12):3314–23.

    Article  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Women’s and Children’s Hospital, Adelaide, Australia

    Christina Ann Boros

  2. University of Adelaide, Adelaide, Australia

    Christina Ann Boros

Authors
  1. Christina Ann Boros
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina Ann Boros .

Editor information

Editors and Affiliations

  1. Centre for MSK Research, University of Manchester and NIHR Biomedical Research Centre, Manchester University Hospital NHS Trust, Manchester, UK

    Janet E. McDonagh

  2. Department of Rheumatology, Sheffield Children’s Hospital, Sheffield, UK

    Rachel S. Tattersall

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Boros, C.A. (2019). Juvenile Dermatomyositis in Adolescents and Young Adults. In: McDonagh, J., Tattersall, R. (eds) Adolescent and Young Adult Rheumatology In Clinical Practice. In Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-95519-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-95519-3_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-95518-6

  • Online ISBN: 978-3-319-95519-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation